中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.017 seconds)

    EFFICIENTLY REPLICABLE HEPTITIS C VIRUS MUTANT, A HEPTITIS C VIRUS MUTANT COMPRISING REPORTER GENE, A METHOD OF PREPARING OF HCV VACCINE USING THE SAME AND A METHOD OF SCREENING ANTI HCV COMPOSITION USING THE SAME
    1.
    发明申请
    EFFICIENTLY REPLICABLE HEPTITIS C VIRUS MUTANT, A HEPTITIS C VIRUS MUTANT COMPRISING REPORTER GENE, A METHOD OF PREPARING OF HCV VACCINE USING THE SAME AND A METHOD OF SCREENING ANTI HCV COMPOSITION USING THE SAME 审中-公开
    高效可选择性HEPTITIS C病毒突变体，包含报告基因的HEPTITIS C病毒突变体，使用该酶的HCV疫苗的制备方法和使用该方法筛选抗HCV组合物的方法

    公开(公告)号：US20100215696A1

    公开(公告)日：2010-08-26

    申请号：US12597747

    申请日：2008-04-28

    Applicant: Sung-Key Jang ,  Chon Saeng Kim

    Inventor： Sung-Key Jang ,  Chon Saeng Kim

    IPC: A61K39/29 ,  C12N15/51 ,  C12N7/01 ,  C12N15/63 ,  C12N5/00 ,  C07K16/00 ,  C12Q1/70 ,  A61K48/00 ,  A61K35/76 ,  A61P31/12

    CPC classification number: C12N15/86 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/525 ,  C07K14/005 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24243 ,  G01N2333/186 ,  G01N2500/10

    Abstract: The present invention relates an efficiently replicating a modified hepatitis virus (HCV) mutant, and a modified HCV further comprising reporter gene, a method of preparing HCV vaccine using the same, and a method of screening anti-HCV material using the same. The present invention is to overcome the defect that the conventional HCV cell culture systems are unable to produce a sufficient amount of virus, thereby causing it difficult to efficiently induce or measure HCV infection. Because the present invention can allow production of HCV in a large amount an efficiently observing HCV infection in a living cell, it can make it possible to achieve many studies that were previously highly challenging, including studies on infection routes, and assembly and release of HCV. In addition, the present invention contributes to studies for searching anti-HCV agents being inhibiting all stages of the HCV life cycle, not being limited to HCV replication.

    Abstract translation: 本发明涉及有效复制改良型肝炎病毒（HCV）突变体和进一步包含报告基因的修饰型HCV，使用该HCV的疫苗的制备方法以及使用该HCV筛选抗HCV材料的方法。 本发明是为了克服常规HCV细胞培养体系不能产生足够量的病毒的缺陷，从而难以有效地诱导或测定HCV感染。 因为本发明能够大量生产HCV，能有效地观察活细胞中的HCV感染，所以可以实现以前高度挑战性的许多研究，包括感染途径的研究以及HCV的组装和释放 。 此外，本发明有助于搜索抑制HCV生命周期的所有阶段的抗HCV药物的研究，而不仅限于HCV复制。

    METHOD OF DETECTING A TARGET USING APTAMER-MEDIATED PROTEIN PRECIPITATION ASSAY
    5.
    发明申请
    METHOD OF DETECTING A TARGET USING APTAMER-MEDIATED PROTEIN PRECIPITATION ASSAY 审中-公开
    使用APTAMER介导的蛋白质降解测定法检测目标的方法

    公开(公告)号：US20130059292A1

    公开(公告)日：2013-03-07

    申请号：US13599125

    申请日：2012-08-30

    Applicant: Ki-Seok KIM ,  Seung-Jin Lee ,  Dong-Il Han ,  Sung-Ho Ryu ,  Sung-Key Jang

    Inventor： Ki-Seok KIM ,  Seung-Jin Lee ,  Dong-Il Han ,  Sung-Ho Ryu ,  Sung-Key Jang

    IPC: G01N33/53 ,  C12Q1/70 ,  C12Q1/68

    CPC classification number: G01N33/54306

    Abstract: The present invention relates to a method and detection kit for determining a presence of one or more proteins using aptamer-mediated pull-down assays. Specifically, a reproducible a protein precipitation (Co-AP/AP) method is provided to identify physiologically relevant protein-protein interactions by using target protein-specific aptamers, and to confirm its superior performance over antibody based protein precipitation (Co-IP/IP) methods in terms of its protein pull-down performance.

    Abstract translation: 本发明涉及一种用于使用适体介导的下拉测定来测定一种或多种蛋白质的存在的方法和检测试剂盒。 具体来说，提供了可重复的蛋白沉淀（Co-AP / AP）方法，通过使用靶蛋白特异性适体来鉴定与生物相关的蛋白质 - 蛋白质相互作用，并确认其优于基于抗体的蛋白质沉淀（Co-IP / IP ）方法在其蛋白质下拉性能方面。

    NOVEL USE OF GRP 94 IN VIRUS INFECTION
    7.
    发明申请
    NOVEL USE OF GRP 94 IN VIRUS INFECTION 审中-公开
    GRP 94在病毒感染中的新用途

    公开(公告)号：US20100273144A1

    公开(公告)日：2010-10-28

    申请号：US12814413

    申请日：2010-06-11

    Applicant: Sung-Key Jang ,  Song-Hee Lee

    Inventor： Sung-Key Jang ,  Song-Hee Lee

    IPC: C12Q1/70

    CPC classification number: G01N33/68 ,  A61K31/711 ,  G01N33/576 ,  G01N2500/00

    Abstract: A novel use of GRP 94 in treatment of virus infection is provided. More specifically, a method of inhibiting virus infection by inhibiting expression of GRP 94 and/or inactivating activity of GRP 94, and a method of developing drugs for preventing and/or treating virus infection and/or diseases caused by virus infection by using GRP 94 as a target are provided.

    Abstract translation: 提供GRP 94在病毒感染治疗中的新用途。 更具体地，通过抑制GRP94的表达和/或灭活GRP94的活性来抑制病毒感染的方法，以及通过使用GRP 94来开发用于预防和/或治疗由病毒感染引起的病毒感染和/或疾病的药物的方法 作为目标提供。

Patent Agency Ranking